cefiderocol (Fetroja)
Jump to navigation
Jump to search
Introduction
FDA-approved Nov 2019
Indications
- multidrug-resistant gram-negative pathogens[2]
- carbapenem-resistant Acinetobacter baumannii infections[4]
- complicated urinary tract infections, including pyelonephritis[1][3]
- ventilator-associated pneumonia[5]
Antimicrobial activity
- gram-negative pathogen
- poor in vitro activity against gram-positive or anaerobic bacteria
Mechanism of action
- siderophore cephalosporin
- stability against most beta-lactamases including including serine- & metallo- carbapenemases[2]
- able to overcome all 3 major mechanisms of carbapenem resistance
- porin channel alterations
- beta-lactamase inactivation
- efflux pump overproduction
- binds to ferric iron
- bind to penicillin-binding proteins
- inhibits cell wall synthesis in the bacterial cells
More general terms
References
- ↑ 1.0 1.1 Business Wire. Oct 16, 2019 U.S. FDA Advisory Committee Recommends Approval of Cefiderocol for Treatment of Complicated Urinary Tract Infections. https://www.businesswire.com/news/home/20191016005916/en/U.S.-FDA-Advisory-Committee-Recommends-Approval-Cefiderocol
- ↑ 2.0 2.1 2.2 Dobias J, Denervaud-Tendon V, Poirel L, Nordmann P. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017 Dec;36(12):2319-2327. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28748397 https://link.springer.com/article/10.1007%2Fs10096-017-3063-z
- ↑ 3.0 3.1 Brooks M FDA OKs New Antibacterial Cefiderocol (Fetroja) for Complicated UTI. Medscape. Nov 15, 2019. https://www.medscape.com/viewarticle/921401
FDA NEWS RELEASE. Nov 14, 2019 FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance. https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts - ↑ 4.0 4.1 4.2 Susman E Novel Siderophore Cephalosporin Nets Promising Results in Tough-to-Treat CRAB. PROVE offers real-world data in carbapenem-resistant Acinetobacter baumannii. MedPage Today October 23, 2022 https://www.medpagetoday.com/meetingcoverage/idweek/101369
- ↑ 5.0 5.1 Rapid Review Quiz: Hospital-Acquired Pneumonia Medscape. Sept 15, 2022 https://reference.medscape.com/viewarticle/980567